FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antibody topics
Antibodies
Recombinant
Monoclonal
Monoclonal Antibody
Differentiation
Polynucleotide
Nucleotide
Metabolism
Therapeutical
Combination Therapy
Bendamustine
Chemokine Receptor
Immune Response
Protein A Affinity Chromatography
Chromatograph

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibody patents



      
           
This page is updated frequently with new Antibody-related patent applications. Subscribe to the Antibody RSS feed to automatically get the update: related Antibody RSS feeds. RSS updates for this page: Antibody RSS RSS


Identification of antigen-specific adaptive immune responses using arm-pcr and high-throughput sequencing

Date/App# patent app List of recent Antibody-related patents
08/21/14
20140235835
 Calicheamicin derivative-carrier conjugates patent thumbnailCalicheamicin derivative-carrier conjugates
Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (lcf) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described.
08/21/14
20140235833
 Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same patent thumbnailMethod of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same
The present invention relates to an isolated antibody against her1, an isolated antibody against cd147, an isolated antibody against cd73, and an isolated antibody against epcam; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies.
08/21/14
20140235827
 Mouse anti-aggrus monoclonal antibodies patent thumbnailMouse anti-aggrus monoclonal antibodies
The present invention provides a monoclonal antibody or a functional fragment thereof, capable of recognizing aggrus epitope comprising an amino-acid sequence represented by a sequence id 1, 3, or 4, and the monoclonal antibody or the functional fragment thereof produced from a hybridoma with deposit id of ferm bp-11446, ferm bp-11447, ferm bp-11448 or ferm bp-11449. The present invention provides the hybridoma, and further an aggrus-clec-2 binding inhibitor and a pharmaceutical composition for inhibition of platelet aggregation, prevention of cancer metastasis, or treatment of tumor or cancer, comprising the monoclonal antibody or the functional fragment thereof..
08/21/14
20140235497
 Identification of antigen-specific adaptive immune responses using arm-pcr and high-throughput sequencing patent thumbnailIdentification of antigen-specific adaptive immune responses using arm-pcr and high-throughput sequencing
Disclosed is a method for correlating at least one amino acid sequence from an antibody isolated from human or animal blood with at least one dna sequence corresponding to the antibody in the immunorepertoire of the human or animal. The method also provides a means for pairing heavy and light chains to produce synthesized monoclonal antibodies..
08/21/14
20140235492
 Methods for preparing single domain antibody microarrays patent thumbnailMethods for preparing single domain antibody microarrays
The present invention relates to a method for preparing sd ab microarray comprising the step consisting of: —i) providing a host cell capable of expressing a biotinylation enzyme —ii) transforming said host cell with a nucleic acid encoding for a fusion protein wherein a single domain antibody is fused at its carboxy terminal end to a biotinylation peptide —iii) culturing said host cell in presence of biotin in such a way that said fusion protein and biotinylation enzyme are expressed, resulting in biotinylation of said fusion protein —iv) lysing said host cell as cultured at step iii) —v) spotting the lysate obtained at step iv) on a solid sup port coated with an agent selected from the group consisting of avidin, streptavidin and/or any art known derivative of these agents a further object of the invention relates to a sd ab microarray obtainable by the method of the invention.. .
08/21/14
20140235482
 Immunoglobulin fc polypeptides patent thumbnailImmunoglobulin fc polypeptides
Methods and compositions involving polypeptides having an aglycosylated antibody fc domain. In certain embodiments, polypeptides have an aglycosylated fc domain that contains one or more substitutions compared to a native fc domain.
08/21/14
20140235480
 Ultra-sensitive detection of analytes patent thumbnailUltra-sensitive detection of analytes
The present invention provides devices and methods for ultra-sensitive detection of analytes of interest in a rapid and convenient manner. A portable handheld device having replaceable cartridges adaptable for detection of a wide array of analytes (e.g., biological, environmental, and the like) is provided.
08/21/14
20140235478
 Measurement and comparison of immune diversity by high-throughput sequencing patent thumbnailMeasurement and comparison of immune diversity by high-throughput sequencing
High-throughput long read sequencing is used to perform immunogenomic characterization of expressed antibody repertoires in the context of vaccination. Informatic analysis allows global characterizations of isotype distributions, determination of the lineage structure of the repertoire and measure age and antigen related mutational activity.
08/21/14
20140234905
 Cell culture improvements patent thumbnailCell culture improvements
The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture..
08/21/14
20140234899
 Process for antibody g1 glycoform production patent thumbnailProcess for antibody g1 glycoform production
The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment or immunoglobulin fusion with g1 glycostructure comprising incubating with a galactosyltransferase, a sialyltransferase, a beta-1,4-galactosidase and a sialidase, whereby the galactosyltransferase is added in more than one aliquot during the incubating.. .
08/21/14
20140234893
Heterologous intron within an immunoglobulin domain
The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns..
08/21/14
20140234885
Methods for optimizing domain stability of binding proteins
Provided are methods for measuring the inherent stability of intrachain disulphide-containing domains (e.g., antibody variable domains) and for optimizing the positioning of intrachain disulphide-containing domains within a protein (e.g., a multispecific binding protein, e.g., a dvd-ig). Also provided are methods of making multispecific binding proteins (e.g., dvd-ig molecules) comprising two or more antibody variable domains in which the antibody variable domains are optimally positioned within the multispecific binding proteins to enhance stability of the multispecific binding protein.
08/21/14
20140234875
Methods predicting risk of an adverse clinical outcome
Provided are methods for evaluating the risk of an adverse clinical outcome in a subject, deciding whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis), or to initiate or terminate treatment, selecting a subject for participation in a clinical study, and selecting a therapeutic treatment for a subject that include determining a level of st2 in a biological sample from the subject and determining a level of galectin-3 in a biological sample from the subject. Kits are also provided that contain an antibody that specifically binds to st2, an antibody that specifically binds to galectin-3, and instructions for using the kit to evaluate the risk of an adverse clinical outcome in a subject, to decide whether to discharge or continue treating a subject (e.g., treatment on an inpatient basis) or to initiate or terminate treatment, to select a subject for participation in a clinical study, and/or to select treatment for a subject..
08/21/14
20140234863
Immunoassay methods
The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.. .
08/21/14
20140234344
Anti-cd40 antibodies and uses thereof
The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-cd40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-cd40 antibody or fragments thereof, including humanized antibodies..
08/21/14
20140234340
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction..
08/21/14
20140234338
Therapeutic agent for use in a method of treating psoriasis or atopic dermatitis
The present invention provides a therapeutic agent for psoriasis or atopic dermatitis, and comprises anti-staphylococcus aureus antibodies as the active ingredient. A therapeutic agent for psoriasis or atopic dermatitis is specifically provided.
08/21/14
20140234337
Antibody and antibody-containing composition
For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom.
08/21/14
20140234335
Method and reagent for diagnosis and/or evaulation of progression of graft-versus-host disease
Disclosed is a method of diagnosing graft-versus-host disease, comprising measuring the level of ccl8 protein in a sample obtained from a subject as an indicator for the diagnosis or course of graft-versus-host disease. Also a diagnostic reagent for graft-versus-host disease comprising an anti-ccl8 antibody is disclosed.
08/21/14
20140234327
Monoclonal antibody against human non-small cell lung carcinoma and use thereof
The invention discloses a monoclonal antibody against human non-small cell lung carcinoma and a use of the monoclonal antibody. The monoclonal antibody is secreted by a hybridoma cell strain which is deposited as cctcc access number no.: c201172.
08/21/14
20140234325
Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs
Antibodies to seb, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infection are provided, as well as assays for identifying additional agents useful in such therapies.
08/21/14
20140234324
Methods for treating a tumor using an antibody that specifically binds grp94
Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated braf.
08/21/14
20140234323
Compositions and methods for detecting tlr3
The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to tlr3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect tlr3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects..
08/21/14
20140234317
Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents
Methods are disclosed for preventing toxic drug-drug interactions during combination cancer therapy with a drug that is an anti-erbb3 agent, such as an anti-erbb3 antibody, together with a drug that is a tyrosine kinase inhibitor and/or a drug that binds to alpha-1 acid glycoprotein (e.g., erlotinib). Health care practitioners obtaining any one of the drugs are warned that when co-administering the drug that is an anti-erbb3 agent with either or both of a drug that is a tyrosine kinase inhibitor and a drug that binds to alpha-1 acid glycoprotein, at least one of the co-administered drugs should be administered using a reduced dosage to prevent toxicity.
08/21/14
20140234316
Vaccibodies targeted to cross-presenting dendritic cells
The present invention relates to recombinant fusion proteins targeted to dendritic cells and uses thereof. In particular, the present invention relates to fusion proteins comprising an antibody component and a targeting components, and uses of such fusion proteins to trigger immune responses..
08/21/14
20140234315
Scfv antibodies which pass epithelial and/or endothelial layers
Scfv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said soluble and stable framework with cdrs that bind specifically to said antigen, or mutating the framework of said non-human antibody towards the sequence of said soluble and stable framework, to generate scfv antibodies, (iii) testing the generated antibody for solubility and stability, and testing the generated antibody for antigen binding, and (iv) selecting an scfv that is soluble, stable and binds to the antigen specifically. Also provided are pharmaceutical compositions comprising said scfv antibody, methods of treatment and diagnosis for diseases related to over expression of antigens that are specifically bound by said antibody..
08/21/14
20140234313
Soluble polypeptides
The invention relates generally to polypeptides, such as antibody molecules, that demonstrate high stability and solubility. In particular, the invention relates to polypeptides comprising paired vl and vh domains that demonstrate soluble expression and folding in a reducing or intracellular environment.
08/21/14
20140234309
Antibody-mediated transduction of heat shock proteins into living cells
The invention provides for a fusion protein comprising a 3e10 fv joined to a hsp-70, hsp-27, hsp-90 or grp-78or portion thereof, and optionally, the 3e10 fv comprising an amino acid sequence agih at its amino terminus.. .
08/21/14
20140234305
Methods of treatment using bevacizumab
Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-vegf agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of vegf signaling), or a combination therapy that includes co-administering an anti-vegf agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (nsaid) to a subject..
08/21/14
20140234304
Human tissue factor antibody and uses thereof
The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor f3) signaling but which does not interfere with factor vii binding or fx binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs..
08/21/14
20140234303
Treatment of neurological conditions
The present invention is directed to a method for treating an inflammatory neurodegenerative condition of the cns in a subject comprising administering to said subject a g-csf or g-csfr inhibiting agent selected from the group consisting of an antibody specific for g-csf, a soluble g-csfr or a g-csf-binding portion thereof and a 20 to 30 nucleotide sense or antisense molecule targeted to a nucleic acid molecule encoding g-csf.. .
08/21/14
20140234300
Method of modulating the activity of functional immune molecules
The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.. .
08/21/14
20140234298
Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
The present disclosure describes a pharmaceutical combination of an anti-cd20 antibody and an anti-gm-csf antibody. Said combinations are highly efficacious in the treatment of b cell malignancies and inflammatory disorders..
08/21/14
20140234297
Antibody constant domain regions and uses thereof
The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. Dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more fcrs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region..
08/21/14
20140234285
Method for therapeutic angiogenesis
The present invention relates to the e2epf ucp-vhl interaction and the uses thereof, more precisely a method for increasing or reducing vhl activity or level by regulating ucp activity or level to inhibit cancer cell proliferation or metastasis or to increase angiogenesis. The inhibition of ucp activity is accomplished by any ucp activity inhibitor selected from a group consisting of a small interfering rna (rnai), an antisense oligonucleotide, and a polynucleotide complementarily binding to mrna of ucp, a peptide, a peptide mimetics and an antibody, and a low molecular compound.
08/21/14
20140234230
Stomatological composition
A stomatological composition is provided. The stomatological composition is capable of stably compounding an antibody obtained from a hen egg yolk, and preventing diseases in an oral cavity such as odontonecrosis and periodontal disease from occurring, or improving such diseases in the oral cavity.
08/21/14
20140234222
Use of tnf alpha inhibitor for treatment of erosive polyarthritis
The invention describes methods of treating erosive polyarthritis comprising administering a tnfα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a tnfα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis..
08/21/14
20140234218
Modified variable domain molecules and methods for producing them b
The present disclosure provides an isolated, engineered or non-naturally occurring protein comprising an antibody light chain variable domain (vl) which may comprise at least one negatively charged amino acid positioned between residues 49 to 56 according to the numbering system of kabat, the protein capable of binding specifically to an antigen.. .
08/21/14
20140234214
Methods of treating a tauopathy
The present disclosure provides methods of treating a tauopathy, involving administering an anti-tau antibody. The present disclosure also provides anti-tau antibodies, and formulations comprising same, for use in the methods..
08/21/14
20140234171
Resonant mass sensor
A separate excitation and high sensitive resonant type mass sensor is provided. The resonant type mass sensor 1 includes: an oscillator 3; an vibrator 2 placed on the oscillator 3; and a detecting unit 5 for detecting the resonant frequency of the vibrator 2, and is characterized in that the vibrator 2 and the oscillator 3 are not coupled mechanically and that the vibrator 2 is not mechanically coupled to any members.
08/14/14
20140228548
Viral clearance methods
The invention provides methods for separating a polypeptide of interest (such as an antibody) from a virus. In some embodiments, the methods involve eluting the polypeptide of interest from a protein a resin with an elution buffer have a particular range of conductivity values that minimizes the amount of virus that co-elutes with the polypeptide of interest..
08/14/14
20140228544
Constructs and libraries comprising antibody surrogate light chain sequences
The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising vpreb sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same..
08/14/14
20140228541
Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules
The present application discloses compositions and methods of synthesis and use of 18f- or 19f-labeled molecules of use in pet, spect and/or mr imaging. Preferably, the 18f or 19f is conjugated to a targeting molecule by formation of a complex with a group iiia metal and binding of the complex to a bifunctional chelating agent, which may then be directly or indirectly attached to the targeting molecule.
08/14/14
20140228295
Inhibitors of beta integrin-g protein alpha subunit binding interactions
Provided herein are compounds that inhibit a binding interaction between a β integrin and a g protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog.
08/14/14
20140228249
Detection and assay devices and methods of making and using the same
An article such as a biomolecular detector or biosensor having a nonfouling surface thereon includes: (a) a substrate having a surface portion; (b) a linking layer on the surface portion; and (c) a polymer layer formed on the linking layer; and (d) a first member of a specific binding pair (e.g., a protein, peptide, antibody, nucleic acid, etc.) bound to the polymer layer. Methods of making and using the articles are also described..
08/14/14
20140227800
Method for stabilizing glycerophospholipids and reagents using same
Disclosed is an accurate and stable immunoassay reagent using a glycerophospholipid and a method for stabilizing the reagent. The reagent for assaying an analyte in blood by immune reaction with an antigen when the analyte is an antibody or with an antibody when the analyte is an antigen, wherein a glycerophospholipid and a polyvinylpyrrolidone are incorporated into the immune reaction system..
08/14/14
20140227799
Method for measuring anti-wt1 antibody
Provided is an invention relating to a method for measuring an anti-wt1 antibody in a sample allowing measurement and evaluation of the anti-wt1 antibody with higher accuracy and to use of the method. The method for measuring an anti-wt1 antibody in a sample includes using a polypeptide having antigenicity to the anti-wt1 antibody selected from a polypeptide comprising the amino acid sequence of positions 294-449 in seq id no: 1, a partial polypeptide of the polypeptide, and a polypeptide including an amino acid sequence having deletion, substitution, or addition of one to several amino acids in the amino acid sequence constituting each of these polypeptides and/or a polypeptide having antigenicity to the anti-wt1 antibody selected from a polypeptide comprising the amino acid sequence of positions 181-324 in seq id no: 1, a partial polypeptide of the polypeptide, and a polypeptide including an amino acid sequence having deletion, substitution, or addition of one to several amino acids in the amino acid sequence constituting each of these polypeptides..
08/14/14
20140227797
Diagnostic use of prosomatostatin
The present invention relates to a method for the diagnosis, prognosis, monitoring and risk assessment of disturbances of the gastrointestinal tract activity and/or function and/or disturbances of the nutritional condition, with the exception of somatostatinoma, in a patient comprising the steps of: providing a sample of a bodily fluid of a patient; determining the level of prosomatostatin 1-64 or fragments thereof in said sample; correlating the level of prosomatostatin 1-64 or fragments thereof to the diagnosis, prognosis and risk assessment of disturbances of the gastrointestinal tract activity and/or function and/or disturbances of the nutritional condition, with the exception of somatostatinoma, in said patient, wherein said fragments have a length of at least 6 amino acid residues. The invention also relates to an antibody and a kit containing at least two antibodies..
08/14/14
20140227724
Nucleic acid construct for use in screening for peptide antibody, and screening method using same
The present invention provides a novel tool for simply screening a candidate molecule for an antibody and a method for screening a candidate molecule for an antibody using the tool. A nucleic acid construct includes: (x) an encoding nucleic acid of an antibody candidate, obtained by inserting an encoding nucleic acid of any peptide into an encoding nucleic acid of an antibody; (y) an encoding nucleic acid of a peptide tag; and (z) an encoding nucleic acid of an aptamer that is bindable to the peptide tag are used.
08/14/14
20140227301
Immunogenic compositions against human progastrin peptides
Immunogens against human extended-progastrin species comprise (a) a mimetic peptide comprised of (i) the amino acid sequence of a progastrin or a n- and/or c-terminal processed species of a progastrin joined to (ii) a 7 amino-acid spacer coupled to (b) an immunogenic carrier. Illustrative of the mimetic peptide/spacer combination are a 21 amino-acid peptide (seq id no.: 1) and other, related polypeptides (seq id nos.: 2-5).
08/14/14
20140227299
Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
Where one or more nemorubicin metabolite or analog drug moieties (d) are covalently attached by a linker (l) to an antibody (ab) which binds to one or more tumor-associated antigens or cell-surface receptors. These compounds may be useful in methods of diagnosis or treatment of cancer, and other diseases and disorders..
08/14/14
20140227294
Prolactin receptor binding proteins and uses thereof
The present invention encompasses prlr binding proteins. Specifically, the invention relates to antibodies that are chimeric, cdr grafted and humanized antibodies.
08/14/14
20140227287
Novel anti-human ngf antibody
[means for resolution] an anti-human ngf antibody fab′ fragment comprising a heavy-chain variable region consisting of an amino acid sequence represented by seq id no:6 and a light-chain variable region consisting of an amino acid sequence represented by seq id no:4.. .
08/14/14
20140227283
Anti-axl antibodies and uses thereof
The present invention relates to anti-axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for axl comprising an heavy chain variable region comprising seq id no:2 in the h-cdr1 region, seq id no:3 in the h-cdr2 region and seq id no:4 in the h-cdr3 region; and a light chain variable region comprising seq id no: 6 in the l-cdr1 region, seq id no:7 in the l-cdr2 region and seq id no:8 in the l-cdr3 region.
08/14/14
20140227277
Combination therapy with an anti-cd19 antibody and a purine analog
The present disclosure describes a pharmaceutical combination of an anti-cd19 antibody and a purine analog for the treatment of non-hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.. .
08/14/14
20140227274
Prevention and treatment of amyloidogenic disease
The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient.
08/14/14
20140227264
Drug fusions and conjugates with extended half life
The present invention relates to drug fusions and conjugates that have improved serum half lives. These fusions and conjugates comprise immunoglobulin (antibody) single variable domains and insulinotropic and/or incretin and/or gut peptide molecules.
08/14/14
20140227259
Modified proteins and peptides
The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise c-terminal additions, extensions or tags and/or certain amino acid substitutions.
08/14/14
20140227256
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an adcc-enhanced antibody.. .
08/14/14
20140227251
Methods for identifying antibodies with reduced immunogenicity
The disclosure describes methods of identifying a variant of a reference antibody with reduced immunogenicity as compared to the reference antibody. The disclosure further describes variants of a reference anti-tnf-α antibody having reduced immunogenicity as compared to the reference anti-tnf-α reference antibody..
08/14/14
20140227180
Antibody-sn-38 immunoconjugates with a cl2a linker
The present invention concerns improved methods and compositions for preparing sn-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the sn-38 is attached to the antibody or antibody fragment using a cl2a linker, with 1-12, more preferably 6 or less, most preferably 1-5 sn-38 moieties per antibody or antibody fragment.
08/14/14
20140227178
Humanized anti-hla-dr antibodies
The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
08/07/14
20140223591
Antibody-mediated immunocontraception
The present disclosure generally relates to methods and compositions for contraception. In some embodiments, vector based approaches for contraception are provided..
08/07/14
20140221624
Humanization of rabbit antibodies using a universal antibody framework
The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications..
08/07/14
20140221620
Anti-human p-cadherin (cdh3) recombinant antibody
It is an object to provide a recombinant antibody that is an anti-cdh3 antibody having cytotoxicity on cdh3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention provides a recombinant antibody which specifically reacts with an epitope existing in the amino acids at positions 108 to 131 or at positions 551 to 654 of the amino acid sequence shown in seq id no: 38 that is the extracellular region of human cdh3, and has cytotoxicity against cdh3-expressing cells..
08/07/14
20140221619
Methods and compositions for increasing protein production
The disclosure provides methods and materials for increasing the expression of a protein of interest such as an antibody by a cell. Abc50 expression or activity is increased which increases expression of the protein or antibody of interest.
08/07/14
20140221613
Novel modified protein comprising tandem-type multimer of mutant extracellular domain of protein g
The purpose of the present invention is: to provide an excellent protein which is further reduced in the binding property to an fc region of an immunoglobulin and/or the binding property to an fab region of the immunoglobulin in a weakly acidic region compared with that of a protein containing an extracellular domain of wild-type protein g, and which still keeps a high antibody-binding activity in a neutral region; and to capture and collect an antibody readily using the protein without denaturating the antibody. The present invention relates to: a protein that is reduced in the binding property to an fc region of an immunoglobulin and/or the binding property to an fab region of the immunoglobulin in a weakly acidic region compared with that of a multimer comprising an extracellular domain of wild type one, which is a domain having a binding activity to a protein comprising an fc region of immunoglobulin g, while keeping a high antibody-binding activity in a neutral region, and also has a binding activity to a protein comprising the fc region of immunoglobulin g, wherein the protein comprises a tandem-type multimer of a mutant of the extracellular domain; and others..
08/07/14
20140221609
Activation of sodium potassium atpase
Activation sites on the alpha subunit of sodium potassium atpase have been discovered. It has also been discovered that certain antibodies that bind to the alpha subunit of sodium potassium atpase dramatically increase enzyme activity.
08/07/14
20140221607
Monoclonal antibody and antigens for diagnosing and treating lung disease and injury
The present invention provides methods for diagnosing a patient with emphysema, copd of lung injury caused by tobacco use by detecting the levels of emap ii in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of emap ii.
08/07/14
20140221250
Rationally designed, synthetic antibody libraries and uses therefor
The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system, with or without dh segments derived from other species, and are based on rational design informed by examination of publicly available databases of antibody sequences..
08/07/14
20140221245
Immunoassay methods
The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.. .
08/07/14
20140221235
Biomarker algorithm for determining the time of stroke symptom onset and method
A method of determining the time of stroke symptom onset is provided including obtaining a biological sample from an individual; contacting the biological sample with a detection composition comprising at least one expression mediator of a ly96, arg1, ca4, and a tlr expression mediators, or a combination of these expression mediators, wherein at least one of the expression mediators is associated with an acute phase response of ischemic stroke, for forming a detectable response; and correlating the detectable response with a time of onset of one or more stroke symptoms. A composition is provided having a nucleic acid probe, an antibody, or a purified biomarker that is specific for at least one of a ly96, arg1, ca4, and tlr expression mediators, or a combination of these expression mediators..


Popular terms: [SEARCH]

Antibody topics: Antibodies, Recombinant, Monoclonal, Monoclonal Antibody, Differentiation, Polynucleotide, Nucleotide, Metabolism, Therapeutical, Combination Therapy, Bendamustine, Chemokine Receptor, Immune Response, Protein A Affinity Chromatography, Chromatograph

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibody for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibody with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.5353

3440

1 - 1 - 77